Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
Azaindole derivatives of formula (I): wherein the symbols have the meanings given in the specification, are described. These compounds have a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition. The invention also relates to pharmaceutical compositions containing these compounds, to methods for preparing them, methods for preparing novel intermediates useful for their synthesis, methods for preparing compositions, and uses of such compounds and compositions, for example, their use in administering them to patients to achieve a therapeutic effect in disorders in which nicotinic receptors and/or dopamine transporters are involved, or that can be treated via manipulation of those receptors.
1. A method for preparing a pharmaceutical composition, the method comprising combining a compound of formula (I):
or a tautomer, stereoisomer, or N-oxide thereof, or a pharmacologically acceptable salt of any of the foregoing,
wherein
X is N, and Y and Z are C;
m is 0, and n is chosen from 0 and 1;
R 2 is chosen from a piperidinyl group, a pyrrolidinyl group, a tetrahydropyridinyl group, a morpholinyl group, a azepanyl group, a 1-aza-bicyclo[2.2.2]octanyl group, and a 1-aza-bicyclo[2.2.2]-oct-2-enyl group, which group is either unsubstituted or substituted with at least one substituent chosen from a halogen atom, a (C 1-3 )alkyl group, a phenyl group and a benzyl group;
R 3 is hydrogen; and
R 4 , R 5 and R 6 , which are the same or different, are chosen from a hydrogen atom, a halogen atom, a (C 1-3 )alkyl group, a (C 2-3 )alkynyl group, a CF 3 group, a NH(C 1-3 )alkyl group, a hydroxyl group and a (C 1-3 )alkyloxy group with the proviso that when X is N, Y and Z are C, m is 0, n is 1, R 3 , R 4 , R 5 and R 6 are H, R 2 is not a piperidinyl group, with
a pharmaceutically acceptable carrier and/or at least one pharmaceutically acceptable auxiliary substance.
2. A method for preparing a medicament, the method comprising combining a compound of formula (I):
or a tautomer, stereoisomer, or N-oxide thereof, or a pharmacologically acceptable salt of any of the foregoing,
wherein
X is N, and Y and Z are C;
m is 0, and n is chosen from 0 and 1;
R 2 is chosen from a piperidinyl group, a pyrrolidinyl group, a tetrahydropyridinyl group, a morpholinyl group, a azepanyl group, a 1-aza-bicyclo[2.2.2]octanyl group, and a 1-aza-bicyclo[2.2.2]-oct-2-enyl group, which group is either unsubstituted or substituted with at least one substituent chosen from a halogen atom, a (C 1-3 )alkyl group, a phenyl group and a benzyl group;
R 3 is hydrogen; and
R 4 , R 5 and R 6 , which are the same or different, are chosen from a hydrogen atom, a halogen atom, a (C 1-3 )alkyl group, a (C 2-3 )alkynyl group, a CF 3 group, a NH(C 1-3 )alkyl group, a hydroxyl group and a (C 1-3 )alkyloxy group with the proviso that when X is N, Y and Z are C, m is 0, n is 1, R 3 , R 4 , R 5 and R 6 are H, R 2 is not a piperidinyl croup,
with a pharmaceutically acceptable carrier and/or at least one pharmaceutically acceptable auxiliary substance.
3. A method for preparation of a pharmaceutical composition for the treatment of at least one CNS disorder chosen from neuroendocrine, neurological and neuropsychiatric disorders, schizophrenia, memory and learning disabilities, attention deficit hyperactivity disorder, anxiety disorders, depressive disorders, neurodegenerative disorders, Alzheimer's disease, addiction disorders, nicotine addiction, cocaine addiction, amphetamine addiction, eating disorders pain, inflammatory processes, convulsive disorders, ocular disorders, glaucoma, macular degeneration, diabetic retinopathy, cardiovascular and gastrointestinal disorders and cancer, the method comprising combining a compound of formula (I):
or a tautomer, stereoisomer, or N-oxide thereof, or a pharmacologically acceptable salt of any of the foregoing,
wherein
X is N, and Y and Z are C;
m is 0, and n is chosen from 0 and 1;
R 2 is chosen from a piperidinyl group, a pyrrolidinyl group, a tetrahydropyridinyl group, a morpholinyl group, a azepanyl group, a 1-aza-bicyclo[2.2.2]octanyl group, and a 1-aza-bicyclo[2.2.2]-oct-2-enyl group, which group is either unsubstituted or substituted with at least one substituent chosen from a halogen atom, a (C 1-3 )alkyl group, a phenyl group and a benzyl group;
R 3 is hydrogen; and
R 4 , R 5 and R 6 , which are the same or different, are chosen from a hydrogen atom, a halogen atom, a (C 1-3 )alkyl group, a (C 2-3 )alkynyl group, a CF 3 group, a NH(C 1-3 )alkyl group, a hydroxyl group and a (C 1-3 )alkyloxy group with the proviso that when X is N, Y and Z are C, m is 0, n is 1, R 3 , R 4 , R 5 and R 6 are H, R 2 is not a piperidinyl group,
with a pharmaceutically acceptable carrier and/or at least one pharmaceutically acceptable auxiliary substance.
4. A method for preparation of a pharmaceutical composition for the treatment of at least one addiction disorder chosen from nicotine addiction, cocaine addiction and amphetamine addiction, the method comprising combining a compound of formula (I):
or a tautomer, stereoisomer, or N-oxide thereof, or a pharmacologically acceptable salt of any of the foregoing,
wherein
X is N, and Y and Z are C;
m is 0, and n is chosen from 0 and 1;
R 2 is chosen from a piperidinyl group, a pyrrolidinyl group, a tetrahydropyridinyl group, a morpholinyl group, a azepanyl group, a 1-aza-bicyclo[2.2.2]octanyl group, and a 1-aza-bicyclo[2.2.2]-oct -2-enyl group, which group is either unsubstituted or substituted with at least one substituent chosen from a halogen atom, a (C 1-3 )alkyl group, a phenyl group and a benzyl group;
R 3 is hydrogen; and
R 4 , R 5 and R 6 , which are the same or different, are chosen from a hydrogen atom, a halogen atom, a (C 1-3 )alkyl group, a (C 2-3 )alkynyl group, a CF 3 group, a NH(C 1-3 )alkyl group, a hydroxyl group and a (C 1-3 )alkyloxy group with the proviso that when X is N, Y and Z are C, m is 0, n is 1, R 3 , R 4 , R 5 and R 6 are H, R 2 is not a piperidinyl group,
with a pharmaceutically acceptable carrier and/or at least one pharmaceutically acceptable auxiliary substance.